Table 2.
Efficacy of Cediranib in Recurrent Glioblastoma
| Radiographic Response | Cediranib (AZD2171) |
Wong et al20 |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Volumetric criteria | ||||
| Partial | 17/30 | 56.7 | NA | |
| Minor | 6/30 | 20.0 | ||
| Macdonald criteria | ||||
| Partial | 8/30 | 26.6 | NA | |
| APF6 (%) | 31 | 25.8 | 15 | |
| 95% CI | 14.7 to 46.9 | |||
| PFS, days | 117 (N = 31) | 63 | ||
| 95% CI | 82 to 145 | |||
| OS, days | 227 (N = 31) | 175 | ||
| 95% CI | 177 to 293 | |||
Abbreviations: NA, not applicable; APF6, alive and progression free at 6 months; PFS, progression-free survival; OS, overall survival.